| Oct 10 |
J&J takes over heart failure treatment company V-Wave
|
| Oct 10 |
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
|
| Oct 10 |
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
|
| Oct 9 |
MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
|
| Oct 9 |
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
|
| Oct 9 |
J&J closes V-Wave deal, to incur IPR&D charge of $600M in Q4
|
| Oct 9 |
Johnson & Johnson Completes Acquisition of V-Wave
|
| Oct 9 |
Johnson & Johnson price target raised to $178 from $175 at RBC Capital
|
| Oct 9 |
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
|
| Oct 8 |
Should Investors Consider High Yield Dividend Stocks?
|
